Successful IPO
April - June in brief
- Total revenues:
SEK 0 (0) thousand. - Operating profit (EBITDA):
SEK -17,238 (-4,859) thousand. - Result for the period:
SEK -17,670 (5,260) thousand. - Earnings per share:
SEK -1.11 (-0.47). - Cash and cash equivalents at the end of the reporting period:
SEK 8,897 (195) thousand. The money from the rights issue in June,SEK 60 million , was paid into the company's account in July. - Equity/assets ratio as per the end of the reporting period: 88 (134) %.
Events in the quarter
- The Annual General Meeting, held on
April 15 , re-elected Anders Månsson, Christer Fåhraeus, Lars Stigsson andMarcus Larsson as board members, andChristopher Bravery ,Fredrik Tiberg . Ingrid Atteryd Heiman andPeter Buhl Jensen were elected as new board members and thatPeter Buhl Jensen was elected to serve as chairman of the Board of Directors. - The Annual General Meeting resolved to carry out a share split of the company's shares in the ratio 500:1. One existing share of the company will be divided into five hundred shares. After the completion of the split, the number of shares is 12,935,000.
- The Annual General Meeting resolved to establish an employee stock option program 2021/2026 for employees and senior executives in the company.
Amniotics carried out a fully subscribed rights issue that generatedSEK 60 million before transaction costs. The Offering consisted of 1,463,415 units. Each unit consisted of two (2) shares and one (1) warrant of series TO 1. In total 2,926,830 new shares were issued and the and the number of shares at end of the quarter is 15,861,830.
January - June in brief
- Total revenues:
SEK 0 (0) thousand. - Operating profit (EBITDA):
SEK -29,311 (-10,345) thousand. - Result for the period:
SEK -30,170 (11,146) thousand. - Earnings per share:
SEK -1.90 (-1.00). - Cash flow for the period:
SEK 8,387 (-5,517) thousand.
Events after the end of the reporting period
- Nasdaq
Stockholm approved trading ofAmniotics shares and warrants on Nasdaq First North Growth Market and the first day of trading was6 July 2021 .
CEO Statement
The first half of 2021 has shown a tremendous advancement for
During the first six months,
In order for
“We are focused on advancing our broader purpose as an organization, as we aim to pioneer stem cell science for the betterment of humanity.”
Looking ahead - our focus is on the preparing and initiating the PulmoStem™ clinical trial scheduled to recruit the first patient in 2022. In addition, our aim is to advance additional product candidates and pursuing discussions with potential partners with interest in our technology platform and pipeline of innovative regenerative medicines.
We are working diligently to create stakeholder value, and the development in the first six months give us confidence that 2021 will be a busy and interesting year for
Again, thank you for your continued support,
Kåre Engkilde, CEO
© Modular Finance, source